Prometheus Biosciences, Inc.
METHODS FOR MONITORING VEDOLIZUMAB TREATMENT

Abstract:

The disclosure provides a method for predicting that a subject having inflammatory bowel disease (IBD) will have a clinical response or remission to an anti-.alpha.4.beta.7 integrin during the course of therapy by assessing the concentration of the anti-.alpha.4.beta.7 integrin drug at the induction or maintenance phase, respectively in a sample from the subject. The disclosure also provides a method for predicting whether a subject having inflammatory bowel disease (IBD) will be a remitter to an anti-.alpha.4.beta.7 integrin drug treatment regimen by detecting the presence or level of at least one predictive marker.